“$256 Million Deal Sparks Concerns Over Pharma Access to Consumer DNA”
n a development raising new questions about the intersection of medicine, data privacy, and corporate power, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced it has acquired key assets of 23andMe Holding Co. following a bankruptcy auction. The deal, valued at $256 million, includes 23andMe’s flagship Personal Genome Service®, its research and health data divisions, and its […]
Discuss on Nostr!
Nostr Note ID note1h4u83hvm75pnp6qdnpwnaq8lk5jlwpls2xphd8nf7wr378juhwdqr5lr99 Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.